Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension

• Published in: Expert review of clinical pharmacology Vol. 12; no. 12; p. 1073
• Main Authors: Aref, Ahmad A, Geyman, Lawrence S, Zakieh, Abdel-Rahman, Alotaibi, Humoud M
• Format: Journal Article
• Language: English
• Published: England 02-12-2019
• Subjects: Animals; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - adverse effects; Benzoates - administration & dosage; Benzoates - adverse effects; beta-Alanine - administration & dosage; beta-Alanine - adverse effects; beta-Alanine - analogs & derivatives; Drug Combinations; Glaucoma, Open-Angle - drug therapy; Humans; Intraocular Pressure; Latanoprost - administration & dosage; Latanoprost - adverse effects; Ocular Hypertension - drug therapy; Ophthalmic Solutions; latanoprost; netarsudil; Glaucoma treatment; rho-kinase inhibitor; trabecular meshwork
• ISSN: 1751-2441
• DOI: 10.1080/17512433.2019.1701435

: Netarsudil and latanoprost ophthalmic solution (0.02%/0.005%) is indicated for intraocular pressure (IOP) lowering in open-angle glaucoma (OAG) or ocular hypertension (OHTN). The once-daily agent combines the mechanism of action for each of the individual components and provides a new avenue for long-term intraocular pressure control. This review aims to cover the agent's current efficacy and safety data and opine as to its role in glaucoma management.
: This article will cover Phase II-III clinical efficacy and safety data as well as basic science literature pertaining to the agent's mechanism of action and pharmacodynamics. In selecting articles for inclusion in this review, a literature search using the PubMed database was carried out. Cross-referencing was carried out where applicable. We did not use any date or language restrictions in electronic searches.
: Netarsudil and latanoprost ophthalmic solution plays a pivotal role in management of individuals with OAG and OHTN. The agent may be used as first-line therapy to provide substantial IOP-lowering or when additional lowering is indicated and prostaglandins have provided insufficient IOP lowering. The once-daily dosing regimen decreases the risk of inadequate treatment due to nonadherence.